% | $
Quotes you view appear here for quick access.

Corixa Corporation (CRXA) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • genedocteur61 genedocteur61 Apr 9, 2002 12:40 AM Flag


    The only way to make a modest income stream with adjuvants is to do lots of non exclusive licenses with everyone with a vaccine.Adjuvants are only a little more than an excipient. This is not a business unto itself as Ribi is witness to.

    These recent press release are a weak attempt to divert attention from Bexxar, but it will not work with the sophisticated investor.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Vaccine adjuvants are nontrivial scientifically and medically. Without an adjuvant, usually one does not have a vaccine either. As far as I know, there is still only 1 adjuvant (alum) approved in the US for human use and it was approved decades ago. In a lot of side by side comparisons, the ribi adjuvants usually come out far superior.

      That being said, there isn't a lot of money in adjuvants per se. The money comes from the combination with an antigen(s) to produce a better vaccine. A better vaccine translates into fewer injections to acheive immunity and better per centage coverage of those immunized.

      It is better than nothing but while adjuvants might have supported a small company like ribi, it probably won't support a large company like corixa.
      Only in my opinions, be well.